alcohol per volume of
formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate
vehicle per volume of formulation and a sufficient amount of a
ricinoleate vehicle so as to prepare a formulation of at least 45
mgml-1 of fulvestrant.
with dependent claims 5 to 17 to remain unchanged and claims
18. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the pharmaceutical
formulation comprises fulvestrant in solution,15-25 % weight of
a